Achieve Life Sciences (ACHV) 10-Q2023 Q1 Quarterly report

Filed: 9 May 23, 4:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accessing, accredited, acetylcholine, activist, aggressively, anxiety, Black, blood, cardiovascular, checking, closure, concurrently, consummation, coronary, dedicate, dedicated, depository, disadvantage, disagreement, disbursed, downturn, economy, EU, exceeding, extraordinary, fatigue, FDIC, flexibility, foreclose, fundamental, gender, headache, heart, honored, infection, input, leveraged, lung, middle, nitrosamine, offset, persisting, PK, placement, presence, President, pulmonary, race, reclassification, refinance, refinancing, regimen, renegotiate, representation, reverse, secondhand, sector, senior, Shareholder, sleep, steady, successor, tender, terrorism, thought, transfer, Trust, turmoil, undertaken, visit, vulnerability, war, weak, weighted

Removed: Adamed, Aflofarm, agonistic, analyze, antagonistic, Antidote, attack, attend, avoid, Axsome, billion, Brexit, Bristol, broader, Building, Century, charged, consideration, construction, contracting, controversial, Currax, cyber, cytisine, desire, diminished, distancing, Embera, emerging, enrolling, expended, extremely, field, framework, Georgia, GlaxoSmithKline, Grosvenor, growing, halt, home, impressive, improved, impurity, Johnson, Kingdom, laboratory, landlord, leased, mechanism, medicinal, member, Merck, month, NAL, NFL, nominal, nonexclusive, Nordisk, Novo, outbreak, people, Pike, Plc, predicted, predominately, Prevention, prioritization, publication, quarantine, ramped, ready, recommended, reflected, renewed, responded, Ro, scheduled, sooner, staffing, stated, structurally, Suite, surveying, team, tied, Tower, transit, travel, treat, ultimate, underwriter, underwriting, underwritten, unforeseen, Union, unmet, vape, West, widespread, withdrawing, worsen, zpharm

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ACHV transcripts

ACHV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, John Bencich, Chief Executive Officer and Principal Executive and Financial Officer of Achieve Life Sciences, Inc. (the “Company”), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

(1) the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 9, 2023


		/s/ John Bencich
		John Bencich
		Chief Executive Officer (Principal Executive and Financial Officer)